{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:49:06Z","timestamp":1787071746062,"version":"build-2736575974"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>The purpose of the study was to evaluate the clinical characteristics and therapeutic response in patients with meibomitis-related keratoconjunctivitis (MRKC) who were treated with oral cefcapene pivoxil hydrochloride hydrate, and to determine factors associated with favorable outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 62 patients with MRKC, including 31 patients who received a 14-day course of oral cefcapene (100 mg three times daily) in combination with standard warm compression and lid hygiene. These patients were 1:1 propensity score\u2013matched with 31 controls who underwent warm compression and lid hygiene, based on age, sex, meibomian gland expressibility, and meibum quality. Baseline characteristics and posttreatment outcomes \u2013 including corneal staining score (CSS) and ocular surface disease index (OSDI) \u2013 were compared between the groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      One month after treatment, mean CSS was significantly lower in the cefcapene group (0.55 \u00b1 0.65) compared with controls (0.86 \u00b1 0.44,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.032*). The cefcapene group also showed higher rates of complete corneal staining resolution (CSS = 0) and greater OSDI improvement, although these outcomes did not reach statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>Adjunctive use of short-term oral cefcapene therapy alongside standard eyelid hygiene measures resulted in a significant reduction in CSSs in patients with MRKC. However, this reduction was not accompanied by a statistically significant improvement in subjective symptoms.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo-d-25-00106","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T13:00:52Z","timestamp":1765198852000},"page":"611-617","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic outcomes of oral cefcapene in meibomitis-related keratoconjunctivitis: A Propensity-matched cohort study"],"prefix":"10.4103","volume":"15","author":[{"given":"Ella (Seo Yeon)","family":"Park","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea"},{"name":"Ophthalmology Center, Seran General Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunmin","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea"},{"name":"Share Bright Vision Eye Clinic, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Yul","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The Institute of Vision Research, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"issue":"Suppl 1","key":"R1-20251223","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1097\/ICO.0b013e31826a04dd","article-title":"Meibomitis-related keratoconjunctivitis:Implications and clinical significance of meibomian gland inflammation","volume":"31","author":"Suzuki","year":"2012","journal-title":"Cornea"},{"key":"R2-20251223","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ajo.2005.02.039","article-title":"Phlyctenular keratitis associated with meibomitis in young patients","volume":"140","author":"Suzuki","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R3-20251223","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jtos.2014.12.002","article-title":"Meibomian glands and ocular surface inflammation","volume":"13","author":"Suzuki","year":"2015","journal-title":"Ocul Surf"},{"key":"R4-20251223","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1167\/iovs.17-23345","article-title":"Inflamed obstructive meibomian gland dysfunction causes ocular surface inflammation","volume":"59","author":"Suzuki","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20251223","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1167\/iovs.10-6997b","article-title":"The international workshop on meibomian gland dysfunction:Report of the definition and classification subcommittee","volume":"52","author":"Nelson","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R6-20251223","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0014-4835(03)00005-8","article-title":"Minocycline effect on meibomian gland lipids in meibomianitis patients","volume":"76","author":"Shine","year":"2003","journal-title":"Exp Eye Res"},{"key":"R7-20251223","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.ajo.2012.06.009","article-title":"Minocycline controls clinical outcomes and inflammatory cytokines in moderate and severe meibomian gland dysfunction","volume":"154","author":"Lee","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R8-20251223","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/bjo.2007.133900","article-title":"Changes in meibomian fatty acids and clinical signs in patients with meibomian gland dysfunction after minocycline treatment","volume":"92","author":"Souchier","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R9-20251223","doi-asserted-by":"crossref","first-page":"4182787","DOI":"10.1155\/2023\/4182787","article-title":"Efficacy of topical azithromycin versus systemic doxycycline in treatment of meibomian gland dysfunction","volume":"2023","author":"Aly Zaky","year":"2023","journal-title":"J Ophthalmol"},{"key":"R10-20251223","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/ajd.12075","article-title":"Non-antibiotic properties of tetracyclines and their clinical application in dermatology","volume":"55","author":"Perret","year":"2014","journal-title":"Australas J Dermatol"},{"key":"R11-20251223","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides:From in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"R12-20251223","first-page":"2970","article-title":"The role of tetracycline in chronic blepharitis. Inhibition of lipase production in staphylococci","volume":"32","author":"Dougherty","year":"1991","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R13-20251223","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/bjo.2006.091579","article-title":"Short term oral minocycline treatment of meibomianitis","volume":"90","author":"Aronowicz","year":"2006","journal-title":"Br J Ophthalmol"},{"key":"R14-20251223","first-page":"664","article-title":"Anti-inflamatory dose doxycycline in the treatment of rosacea","volume":"8","author":"Del Rosso","year":"2009","journal-title":"J Drugs Dermatol"},{"key":"R15-20251223","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2165\/11204850-000000000-00000","article-title":"Doxycycline 40 mg capsules (30 mg immediate-release\/10 mg delayed-release beads):Anti-inflammatory dose in rosacea","volume":"11","author":"McKeage","year":"2010","journal-title":"Am J Clin Dermatol"},{"key":"R16-20251223","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.phrs.2010.10.007","article-title":"Clinical applications of non-antimicrobial tetracyclines in dermatology","volume":"63","author":"Monk","year":"2011","journal-title":"Pharmacol Res"},{"key":"R17-20251223","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/147323000403200604","article-title":"Comparative clinical study of cefcapene pivoxil and cefteram pivoxil in chronic respiratory tract infections by a double-blind method","volume":"32","author":"Saito","year":"2004","journal-title":"J Int Med Res"},{"key":"R18-20251223","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.2147\/OPTH.S89700","article-title":"Associations between signs and symptoms of dry eye disease:A systematic review","volume":"9","author":"Bartlett","year":"2015","journal-title":"Clin Ophthalmol"},{"key":"R19-20251223","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/ICO.0000000000001042","article-title":"Reversibility of gland dropout and significance of eyelid hygiene treatment in meibomian gland dysfunction","volume":"36","author":"Yin","year":"2017","journal-title":"Cornea"},{"key":"R20-20251223","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3341\/kjo.2005.19.4.258","article-title":"The effect of low-dose doxycycline therapy in chronic meibomian gland dysfunction","volume":"19","author":"Yoo","year":"2005","journal-title":"Korean J Ophthalmol"},{"key":"R21-20251223","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/ICO.0b013e318254205f","article-title":"Topical azithromycin and oral doxycycline therapy of meibomian gland dysfunction:A comparative clinical and spectroscopic pilot study","volume":"32","author":"Foulks","year":"2013","journal-title":"Cornea"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:53:10Z","timestamp":1787068390000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-25-00106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-25-00106","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-06-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}